Shooting at a Moving Target—Effectiveness and Emerging Challenges for SARS-CoV-2 Vaccine Development

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.052 · Cited by 20,286

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592 · cited 1×

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119

Structure, function and antigenicity of the SARS-CoV-2 spike glycoprotein

Walls, A. C., Park, Y.-J., Tortorici, M. A., Wall, A., McGuire, A. T., & Veesler, D. (2020) · doi:10.1101/2020.02.19.956581 · Cited by 8,586

Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus

Li, W., Moore, M. J., Vasilieva, N., Sui, J., Wong, S. K., Berne, M. A., Somasundaran, M., Sullivan, J. L., Luzuriaga, K., Greenough, T. C., et al. (2003) · Nature · doi:10.1038/nature02145 · Cited by 5,923

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32661-1 · Cited by 4,616

Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus

Korber, B., Fischer, W. M., Gnanakaran, S., Yoon, H., Theiler, J., Abfalterer, W., Hengartner, N., Giorgi, E. E., Bhattacharya, T., Foley, B., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.043 · Cited by 4,281

Nextstrain: real-time tracking of pathogen evolution

Hadfield, J., Megill, C., Bell, S. M., Huddleston, J., Potter, B., Callender, C., Sagulenko, P., Bedford, T., & Neher, R. A. (2018) · Bioinformatics · doi:10.1093/bioinformatics/bty407 · Cited by 3,154

GISAID: Global initiative on sharing all influenza data – from vision to reality

Shu, Y., & McCauley, J. (2017) · Eurosurveillance · doi:10.2807/1560-7917.es.2017.22.13.30494 · Cited by 3,039

Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant

Lopez Bernal, J., Andrews, N., Gower, C., Gallagher, E., Simmons, R., Thelwall, S., Stowe, J., Tessier, E., Groves, N., Dabrera, G., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2108891 · Cited by 2,889

Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection.

Dan, J. M., Mateus, J., Kato, Y., Hastie, K. M., Yu, E. D., Faliti, C. E., Grifoni, A., Ramirez, S. I., Haupt, S., Frazier, A., et al. (2021) · Science · doi:10.1126/science.abf4063 · Cited by 2,656

RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study

Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615

Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England

Davies, N. G., Abbott, S., Barnard, R. C., Jarvis, C. I., Kucharski, A. J., Munday, J. D., Pearson, C. A. B., Russell, T. W., Tully, D. C., Washburne, A. D., et al. (2021) · Science · doi:10.1126/science.abg3055 · Cited by 2,581

Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England

Davies, N. G., Abbott, S., Barnard, R. C., Jarvis, C. I., Kucharski, A. J., Munday, J. D., Pearson, C. A. B., Russell, T. W., Tully, D. C., Washburne, A. D., et al. (2020) · doi:10.1101/2020.12.24.20248822 · Cited by 2,557

Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa

Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J., Doolabh, D., Pillay, S., San, E. J., Msomi, N., et al. (2020) · doi:10.1101/2020.12.21.20248640 · Cited by 2,535

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

Dagan, N., Barda, N., Kepten, E., Miron, O., Perchik, S., Katz, M. A., Hernán, M. A., Lipsitch, M., Reis, B., & Balicer, R. D. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2101765 · Cited by 2,527 · cited 2×

Detection of a SARS-CoV-2 variant of concern in South Africa

Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J., Doolabh, D., Pillay, S., San, E. J., Msomi, N., et al. (2021) · Nature · doi:10.1038/s41586-021-03402-9 · Cited by 2,510

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

Sadoff, J., Gray, G., Vandebosch, A., Cárdenas, V., Shukarev, G., Grinsztejn, B., Goepfert, P. A., Truyers, C., Fennema, H., Spiessens, B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2101544 · Cited by 2,397

Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination

Greinacher, A., Thiele, T., Warkentin, T. E., Weisser, K., Kyrle, P. A., & Eichinger, S. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2104840 · Cited by 2,259

COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses

Sahin, U., Muik, A., Derhovanessian, E., Vogler, I., Kranz, L. M., Vormehr, M., Baum, A., Pascal, K., Quandt, J., Maurus, D., et al. (2020) · Nature · doi:10.1038/s41586-020-2814-7 · Cited by 1,977

Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding

Starr, T. N., Greaney, A. J., Hilton, S. K., Ellis, D., Crawford, K. H. D., Dingens, A. S., Navarro, M. J., Bowen, J. E., Tortorici, M. A., Walls, A. C., et al. (2020) · Cell · doi:10.1016/j.cell.2020.08.012 · Cited by 1,956

Identifying SARS-CoV-2-related coronaviruses in Malayan pangolins

Lam, T. T., Jia, N., Zhang, Y.-W., Shum, M. H.-H., Jiang, J.-F., Zhu, H., Tong, Y., Shi, Y., Ni, X.-B., Liao, Y., et al. (2020) · Nature · doi:10.1038/s41586-020-2169-0 · Cited by 1,877

A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells

Hoffmann, M., Kleine-Weber, H., & Pöhlmann, S. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.04.022 · Cited by 1,852

Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity

Rydyznski Moderbacher, C., Ramirez, S. I., Dan, J. M., Grifoni, A., Hastie, K. M., Weiskopf, D., Belanger, S., Abbott, R. K., Kim, C., Choi, J., et al. (2020) · Cell · doi:10.1016/j.cell.2020.09.038 · Cited by 1,790

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia

Logunov, D. Y., Dolzhikova, I. V., Shcheblyakov, D. V., Tukhvatulin, A. I., Zubkova, O. V., Dzharullaeva, A. S., Kovyrshina, A. V., Lubenets, N. L., Grousova, D. M., Erokhova, A. S., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00234-8 · Cited by 1,747

Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data

Haas, E. J., Angulo, F. J., McLaughlin, J. M., Anis, E., Singer, S. R., Khan, F., Brooks, N., Smaja, M., Mircus, G., Pan, K., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00947-8 · Cited by 1,564 · cited 1×

Spike mutation D614G alters SARS-CoV-2 fitness

Plante, J. A., Liu, Y., Liu, J., Xia, H., Johnson, B. A., Lokugamage, K. G., Zhang, X., Muruato, A. E., Zou, J., Fontes-Garfias, C. R., et al. (2021) · Nature · doi:10.1038/s41586-020-2895-3 · Cited by 1,558

Site-specific glycan analysis of the SARS-CoV-2 spike

Watanabe, Y., Allen, J. D., Wrapp, D., McLellan, J. S., & Crispin, M. (2020) · Science · doi:10.1126/science.abb9983 · Cited by 1,538

Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil

Faria, N. R., Mellan, T. A., Whittaker, C., Claro, I. M., Candido, D. D. S., Mishra, S., Crispim, M. A. E., Sales, F. C. S., Hawryluk, I., McCrone, J. T., et al. (2021) · Science · doi:10.1126/science.abh2644 · Cited by 1,461

Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination

Schultz, N. H., Sørvoll, I. H., Michelsen, A. E., Munthe, L. A., Lund‐Johansen, F., Ahlén, M. T., Wiedmann, M. K. H., Aamodt, A. H., Skattør, T. H., Tjønnfjord, G. E., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2104882 · Cited by 1,453

Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology

Piccoli, L., Park, Y.-J., Tortorici, M. A., Czudnochowski, N., Walls, A. C., Beltramello, M., Silacci-Fregni, C., Pinto, D., Rosen, L. E., Bowen, J. E., et al. (2020) · Cell · doi:10.1016/j.cell.2020.09.037 · Cited by 1,395

SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity

Zhang, L., Jackson, C. B., Mou, H., Ojha, A., Peng, H., Quinlan, B. D., Rangarajan, E. S., Pan, A., Vanderheiden, A., Suthar, M. S., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19808-4 · Cited by 1,387

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants

(2021) · doi:10.1101/2021.01.15.426911 · Cited by 1,354

Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity

Garcia-Beltran, W. F., Lam, E. C., St. Denis, K., Nitido, A. D., Garcia, Z. H., Hauser, B. M., Feldman, J., Pavlovic, M. N., Gregory, D. J., Poznansky, M. C., et al. (2021) · Cell · doi:10.1016/j.cell.2021.03.013 · Cited by 1,353

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants

Wang, Z., Schmidt, F., Weisblum, Y., Muecksch, F., Barnes, C. O., Finkin, S., Schaefer-Babajew, D., Cipolla, M., Gaebler, C., Lieberman, J. A., et al. (2021) · Nature · doi:10.1038/s41586-021-03324-6 · Cited by 1,343

Maternal and Neonatal Morbidity and Mortality Among Pregnant Women With and Without COVID-19 Infection

Villar, J., Ariff, S., Gunier, R. B., Thiruvengadam, R., Rauch, S. A., Kholin, K. A. M., Roggero, P., Prefumo, F., do Vale, M. S., Cardona–Pérez, J. A., et al. (2021) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/jamapediatrics.2021.1050 · Cited by 1,340

Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants

Weisblum, Y., Schmidt, F., Zhang, F., DaSilva, J., Poston, D., Lorenzi, J. C., Muecksch, F., Rutkowska, M., Hoffmann, H.-H., Michailidis, E., et al. (2020) · eLife · doi:10.7554/elife.61312 · Cited by 1,308

Structure-based design of prefusion-stabilized SARS-CoV-2 spikes

Hsieh, C.-L., Goldsmith, J. A., Schaub, J. M., DiVenere, A. M., Kuo, H.-C., Javanmardi, K., Le, K. C., Wrapp, D., Lee, A. G., Liu, Y., et al. (2020) · Science · doi:10.1126/science.abd0826 · Cited by 1,303

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

Walls, A. C., Park, Y., Tortorici, M. A., Wall, A., McGuire, A. T., & Veesler, D. (2020) · Cell · doi:10.1016/j.cell.2020.11.032 · Cited by 1,283

Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant

Madhi, S. A., Baillie, V., Cutland, C. L., Voysey, M., Koen, A. L., Fairlie, L., Padayachee, S. D., Dheda, K., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2102214 · Cited by 1,257

Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies

Baum, A., Fulton, B. O., Wloga, E., Copin, R., Pascal, K. E., Russo, V., Giordano, S., Lanza, K., Negron, N., Ni, M., et al. (2020) · Science · doi:10.1126/science.abd0831 · Cited by 1,253

Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host

Choi, B., Choudhary, M. C., Regan, J., Sparks, J. A., Padera, R. F., Qiu, X., Solomon, I. H., Kuo, H.-H., Boucau, J., Bowman, K., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2031364 · Cited by 1,246

Comprehensive mapping of mutations to the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human serum antibodies

Greaney, A. J., Loes, A. N., Crawford, K. H. D., Starr, T. N., Malone, K. D., Chu, H. Y., & Bloom, J. D. (2021) · doi:10.1101/2020.12.31.425021 · Cited by 1,178

Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies

Greaney, A. J., Loes, A. N., Crawford, K. H. D., Starr, T. N., Malone, K. D., Chu, H. Y., & Bloom, J. D. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.02.003 · Cited by 1,178

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

Voysey, M., Costa Clemens, S. A., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00432-3 · Cited by 1,119

SARS-CoV-2 evolution during treatment of chronic infection

Kemp, S. A., Collier, D. A., Datir, R. P., Ferreira, I. A. T. M., Gayed, S., Jahun, A., Hosmillo, M., Rees-Spear, C., Mlcochova, P., Lumb, I. U., et al. (2021) · Nature · doi:10.1038/s41586-021-03291-y · Cited by 1,097 · cited 1×

Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine

Heath, P. T., Galiza, E. P., Baxter, D. N., Boffito, M., Browne, D., Burns, F., Chadwick, D. R., Clark, R., Cosgrove, C., Galloway, J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107659 · Cited by 1,085

Structural and Functional Analysis of the D614G SARS-CoV-2 Spike Protein Variant

Yurkovetskiy, L., Wang, X., Pascal, K. E., Tomkins-Tinch, C., Nyalile, T. P., Wang, Y., Baum, A., Diehl, W. E., Dauphin, A., Carbone, C., et al. (2020) · Cell · doi:10.1016/j.cell.2020.09.032 · Cited by 1,025

Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition

Greaney, A. J., Starr, T. N., Gilchuk, P., Zost, S. J., Binshtein, E., Loes, A. N., Hilton, S. K., Huddleston, J., Eguia, R., Crawford, K. H. D., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2020.11.007 · Cited by 1,016

Evolutionary origins of the SARS-CoV-2 sarbecovirus lineage responsible for the COVID-19 pandemic

Boni, M. F., Lemey, P., Jiang, X., Lam, T. T.-Y., Perry, B. W., Castoe, T. A., Rambaut, A., & Robertson, D. L. (2020) · Nature Microbiology · doi:10.1038/s41564-020-0771-4 · Cited by 1,014

Evaluating the Effects of SARS-CoV-2 Spike Mutation D614G on Transmissibility and Pathogenicity

Volz, E., Hill, V., McCrone, J. T., Price, A., Jorgensen, D., O’Toole, Á., Southgate, J., Johnson, R., Jackson, B., Nascimento, F. F., et al. (2021) · Cell · doi:10.1016/j.cell.2020.11.020 · Cited by 1,006

Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination

Scully, M., Singh, D. N., Lown, R. N., Poles, A., Solomon, T., Levi, M. M., Goldblatt, D., Kotouček, P., Thomas, W. D., & Lester, W. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2105385 · Cited by 964

SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness.

Sheikh, A., McMenamin, J., Taylor, B., & Robertson, C. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01358-1 · Cited by 939

Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons

Shimabukuro, T. T., Kim, S. Y., Myers, T. R., Moro, P. L., Oduyebo, T., Panagiotakopoulos, L., Marquez, P. L., Olson, C. K., Liu, R., Chang, K. T., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2104983 · Cited by 927

Long COVID: an overview

Raveendran, A. V., Jayadevan, R., & Sashidharan, S. (2021) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2021.04.007 · Cited by 921

N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2

McCallum, M., De Marco, A., Lempp, F. A., Tortorici, M. A., Pinto, D., Walls, A. C., Beltramello, M., Chen, A., Liu, Z., Zatta, F., et al. (2021) · Cell · doi:10.1016/j.cell.2021.03.028 · Cited by 901 · cited 12×

SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo

Hou, Y. J., Chiba, S., Halfmann, P., Ehre, C., Kuroda, M., Dinnon, K. H., Leist, S. R., Schäfer, A., Nakajima, N., Takahashi, K., et al. (2020) · Science · doi:10.1126/science.abe8499 · Cited by 900

Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants

Abu-Raddad, L. J., Chemaitelly, H., & Butt, A. A. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2104974 · Cited by 899

Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey

Tanriover, M. D., Doğanay, H. L., Akova, M., Güner, H. R., Azap, A., Akhan, S., Köse, Ş., Erdinç, F. Ş., Akalın, E. H., Tabak, Ö. F., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01429-x · Cited by 898

Safety, immunogenicity, and efficacy of the BNT162b2 covid-19 vaccine in adolescents

Frenck, R. W., Klein, N. P., Kitchin, N., Gurtman, A., Absalon, J., Lockhart, S., Perez, J. L., Walter, E. B., Senders, S., Bailey, R., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107456 · Cited by 889

TMPRSS2 and furin are both essential for proteolytic activation of SARS-CoV-2 in human airway cells

Bestle, D., Heindl, M. R., Limburg, H., Van Lam van, T., Pilgram, O., Moulton, H., Stein, D. A., Hardes, K., Eickmann, M., Dolnik, O., et al. (2020) · Life Science Alliance · doi:10.26508/lsa.202000786 · Cited by 815

The furin cleavage site in the SARS-CoV-2 spike protein is required for transmission in ferrets

Peacock, T. P., Goldhill, D. H., Zhou, J., Baillon, L., Frise, R., Swann, O. C., Kugathasan, R., Penn, R., Brown, J. C., Sanchez-David, R. Y., et al. (2021) · Nature Microbiology · doi:10.1038/s41564-021-00908-w · Cited by 802

Single-Shot Ad26 Vaccine Protects Against SARS-CoV-2 in Rhesus Macaques

Mercado, N. B., Zahn, R., Wegmann, F., Loos, C., Chandrashekar, A., Yu, J., Liu, J., Peter, L., McMahan, K., Tostanoski, L. H., et al. (2020) · Nature · doi:10.1038/s41586-020-2607-z · Cited by 789

Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults

Kaabi, N. A., Zhang, Y., Xia, S., Yang, Y., AlQahtani, M., Abdulrazzaq, N. M., Nusair, M. A., Hassany, M., Jawad, J. S., Abdalla, J., et al. (2021) · JAMA · doi:10.1001/jama.2021.8565 · Cited by 766

Recombination, Reservoirs, and the Modular Spike: Mechanisms of Coronavirus Cross-Species Transmission

Graham, R. L., & Baric, R. S. (2009) · Journal of Virology · doi:10.1128/jvi.01394-09 · Cited by 753

Prospective mapping of viral mutations that escape antibodies used to treat COVID-19

Starr, T. N., Greaney, A. J., Addetia, A., Hannon, W. W., Choudhary, M. C., Dingens, A. S., Li, J. Z., & Bloom, J. D. (2021) · Science · doi:10.1126/science.abf9302 · Cited by 743

Economic Consequences of the COVID-19 Outbreak: the Need for Epidemic Preparedness

Pak, A., Adegboye, O. A., Adekunle, A. I., Rahman, K. M., McBryde, E. S., & Eisen, D. P. (2020) · Frontiers in Public Health · doi:10.3389/fpubh.2020.00241 · Cited by 721

Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with Cancer

Avanzato, V. A., Matson, M. J., Seifert, S. N., Pryce, R., Williamson, B. N., Anzick, S. L., Barbian, K., Judson, S. D., Fischer, E. R., Martens, C., et al. (2020) · Cell · doi:10.1016/j.cell.2020.10.049 · Cited by 720

Vaccine Breakthrough Infections with SARS-CoV-2 Variants

Hacisuleyman, E., Hale, C., Saito, Y., Blachere, N. E., Bergh, M., Conlon, E. G., Schaefer-Babajew, D. J., DaSilva, J., Muecksch, F., Gaebler, C., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2105000 · Cited by 716

COVID-19 vaccines: modes of immune activation and future challenges

Teijaro, J. R., & Färber, D. L. (2021) · Nature reviews. Immunology · doi:10.1038/s41577-021-00526-x · Cited by 714

Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021

Thompson, M. G., Burgess, J. L., Naleway, A. L., Tyner, H. L., Yoon, S. K., Meece, J., Olsho, L. E. W., Caban-Martinez, A. J., Fowlkes, A., Lutrick, K., et al. (2021) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7013e3 · Cited by 707

Coronavirus disease 2019 vaccine response in pregnant and lactating women: a cohort study

Gray, K. J., Bordt, E. A., Atyeo, C., Deriso, E., Akinwunmi, B., Young, N., Baez, A. M., Shook, L. L., Cvrk, D., James, K., et al. (2021) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2021.03.023 · Cited by 699

Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-2 in the United Kingdom, October to November 2020

Leung, K., Shum, M. H., Leung, G. M., Lam, T. T., & Wu, J. T. (2021) · Eurosurveillance · doi:10.2807/1560-7917.es.2020.26.1.2002106 · Cited by 694

Loss of furin cleavage site attenuates SARS-CoV-2 pathogenesis

Johnson, B. A., Xie, X., Bailey, A. L., Kalveram, B., Lokugamage, K. G., Muruato, A., Zou, J., Zhang, X., Juelich, T., Smith, J. K., et al. (2021) · Nature · doi:10.1038/s41586-021-03237-4 · Cited by 694

BNT162b vaccines protect rhesus macaques from SARS-CoV-2

Vogel, A. B., Kanevsky, I., Che, Y., Swanson, K. A., Muik, A., Vormehr, M., Kranz, L. M., Walzer, K. C., Hein, S., Güler, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03275-y · Cited by 694

Adenoviruses as vaccine vectors

Tatsis, N., & Ertl, H. C. J. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.07.013 · Cited by 669

Long COVID in a prospective cohort of home-isolated patients

Blomberg, B., Mohn, K. G.-I., Brokstad, K. A., Zhou, F., Linchausen, D. W., Hansen, B.-A., Lartey, S., Onyango, T. B., Kuwelker, K., Sævik, M., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01433-3 · Cited by 659

Longitudinal Analysis Reveals Distinct Antibody and Memory B Cell Responses in SARS-CoV2 Naïve and Recovered Individuals Following mRNA Vaccination

(2021) · doi:10.1101/2021.03.03.21252872 · Cited by 655

Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals after mRNA vaccination

Goel, R. R., Apostolidis, S. A., Painter, M. M., Mathew, D., Pattekar, A., Kuthuru, O., Gouma, S., Hicks, P., Meng, W., Rosenfeld, A. M., et al. (2021) · Science Immunology · doi:10.1126/sciimmunol.abi6950 · Cited by 655

Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant

Deng, X., Garcia-Knight, M. A., Khalid, M. M., Servellita, V., Wang, C., Morris, M. K., Sotomayor-González, A., Glasner, D. R., Reyes, K. R., Gliwa, A. S., et al. (2021) · Cell · doi:10.1016/j.cell.2021.04.025 · Cited by 651

Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization

Wang, P., Casner, R. G., Nair, M. S., Wang, M., Yu, J., Cerutti, G., Liu, L., Kwong, P. D., Huang, Y., Shapiro, L., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.04.007 · Cited by 636

Prospective mapping of viral mutations that escape antibodies used to treat COVID-19Preprint

Starr, T. N., Greaney, A. J., Addetia, A., Hannon, W. W., Choudhary, M., Dingens, A. S., Li, J. Z., & Bloom, J. (2020) · bioRxiv · doi:10.1101/2020.11.30.405472 · Cited by 633

Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera

Xie, X., Liu, Y., Liu, J., Zhang, X., Zou, J., Fontes-Garfias, C. R., Xia, H., Swanson, K. A., Cutler, M., Cooper, D., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01270-4 · Cited by 628

Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera

(2021) · doi:10.21203/rs.3.rs-143532/v1 · Cited by 628

Increased Resistance of SARS-CoV-2 Variant P.1 to Antibody Neutralization

(2021) · doi:10.1101/2021.03.01.433466 · Cited by 626

Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity

Thomson, E. C., Rosen, L. E., Shepherd, J. G., Spreafico, R., da Silva Filipe, A., Wojcechowskyj, J. A., Davis, C., Piccoli, L., Pascall, D. J., Dillen, J., et al. (2021) · Cell · doi:10.1016/j.cell.2021.01.037 · Cited by 606

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial

Emary, K. R. W., Golubchik, T., Aley, P. K., Ariani, C. V., Angus, B., Bibi, S., Blane, B., Bonsall, D., Cicconi, P., Charlton, S., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00628-0 · Cited by 603

A Novel Bat Coronavirus Closely Related to SARS-CoV-2 Contains Natural Insertions at the S1/S2 Cleavage Site of the Spike Protein

Zhou, H., Chen, X., Hu, T., Li, J., Song, H., Liu, Y., Wang, P., Liu, D., Yang, J., Holmes, E. C., et al. (2020) · Current Biology · doi:10.1016/j.cub.2020.05.023 · Cited by 589

SARS-CoV-2 spike L452R variant evades cellular immunity and increases infectivity

Motozono, C., Toyoda, M., Zahradnik, J., Saito, A., Nasser, H., Tan, T. S., Ngare, I., Kimura, I., Uriu, K., Kosugi, Y., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.06.006 · Cited by 586

Antibody evasion by the P.1 strain of SARS-CoV-2

Dejnirattisai, W., Zhou, D., Supasa, P., Liu, C., Mentzer, A. J., Ginn, H. M., Zhao, Y., Duyvesteyn, H. M. E., Tuekprakhon, A., Nutalai, R., et al. (2021) · Cell · doi:10.1016/j.cell.2021.03.055 · Cited by 583

SARS-CoV-2 spike D614G change enhances replication and transmission

Zhou, B., Thao, T. T. N., Hoffmann, D., Taddeo, A., Ebert, N., Labroussaa, F., Pohlmann, A., King, J., Steiner, S., Kelly, J. N., et al. (2021) · Nature · doi:10.1038/s41586-021-03361-1 · Cited by 538

Neutralizing Activity of BNT162b2-Elicited Serum

Liu, Y., Liu, J., Xia, H., Zhang, X., Fontes-Garfias, C. R., Swanson, K. A., Cai, H., Sarkar, R., Chen, W., Cutler, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2102017 · Cited by 537

Recurrent deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape

McCarthy, K. R., Rennick, L. J., Nambulli, S., Robinson-McCarthy, L. R., Bain, W. G., Haidar, G., & Duprex, W. P. (2021) · Science · doi:10.1126/science.abf6950 · Cited by 535

SARS-CoV-2 D614G spike mutation increases entry efficiency with enhanced ACE2-binding affinity

Ozono, S., Zhang, Y., Ode, H., Sano, K., Tan, T. S., Imai, K., Miyoshi, K., Kishigami, S., Ueno, T., Iwatani, Y., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21118-2 · Cited by 522

Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms

Tortorici, M. A., Beltramello, M., Lempp, F. A., Pinto, D., Dang, H. V., Rosen, L. E., McCallum, M., Bowen, J., Minola, A., Jaconi, S., et al. (2020) · Science · doi:10.1126/science.abe3354 · Cited by 510

SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice

Tian, J.-H., Patel, N., Haupt, R., Zhou, H., Weston, S., Hammond, H., Logue, J., Portnoff, A. D., Norton, J., Guebre-Xabier, M., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20653-8 · Cited by 508

SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape

Starr, T. N., Czudnochowski, N., Liu, Z., Zatta, F., Park, Y., Addetia, A., Pinto, D., Beltramello, M., Hernandez, P., Greaney, A. J., et al. (2021) · Nature · doi:10.1038/s41586-021-03807-6 · Cited by 503

Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial

Liu, X., Shaw, R. H., Stuart, A. S. V., Greenland, M., Aley, P. K., Andrews, N. J., Cameron, J. C., Charlton, S., Clutterbuck, E., Collins, A. M., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01694-9 · Cited by 480

Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016

Starr, T. N., Greaney, A. J., Dingens, A. S., & Bloom, J. D. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100255 · Cited by 470

Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies

Greaney, A. J., Starr, T. N., Barnes, C. O., Weisblum, Y., Schmidt, F., Caskey, M., Gaebler, C., Cho, A., Agudelo, M., Finkin, S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24435-8 · Cited by 433 · cited 1×

Respiratory Syncytial Virus Vaccination during Pregnancy and Effects in Infants

Madhi, S. A., Polack, F. P., Piedra, P. A., Muñoz, F. M., Trenholme, A. A., Simões, E. A. F., Swamy, G. K., Agrawal, S., Ahmed, K., August, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1908380 · Cited by 420

Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination

Muir, K.-L. E., Kallam, A., Koepsell, S. A., & Gundabolu, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2105869 · Cited by 415

SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern

McCallum, M., Bassi, J., De Marco, A., Chen, A., Walls, A. C., Di Iulio, J., Tortorici, M. A., Navarro, M.-J., Silacci-Fregni, C., Saliba, C., et al. (2021) · Science · doi:10.1126/science.abi7994 · Cited by 412

Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine

Wu, K., Werner, A. P., Koch, M., Choi, A., Narayanan, E., Stewart-Jones, G. B. E., Colpitts, T., Bennett, H., Boyoglu-Barnum, S., Shi, W., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2102179 · Cited by 409

Structural impact on SARS-CoV-2 spike protein by D614G substitution

Zhang, J., Cai, Y., Xiao, T., Lu, J., Peng, H., Sterling, S. M., Walsh, R. M., Rits‐Volloch, S., Zhu, H., Woosley, A. N., et al. (2021) · Science · doi:10.1126/science.abf2303 · Cited by 407

Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B.1.1.7

Meng, B., Kemp, S. A., Papa, G., Datir, R. P., Ferreira, I. A. T. M., Marelli, S., Harvey, W. T., Lytras, S., Mohamed, A., Gallo, G., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109292 · Cited by 407

Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection

Zuo, J., Dowell, A. C., Pearce, H., Verma, K., Long, H. M., Begum, J., Aiano, F., Amin-Chowdhury, Z., Hoschler, K., Brooks, T., et al. (2021) · Nature Immunology · doi:10.1038/s41590-021-00902-8 · Cited by 392

Rapid and stable mobilization of CD8+ T cells by SARS-CoV-2 mRNA vaccine

Oberhardt, V., Luxenburger, H., Kemming, J., Schulien, I., Ciminski, K., Giese, S., Csernalabics, B., Lang-Meli, J., Janowska, I., Staniek, J., et al. (2021) · Nature · doi:10.1038/s41586-021-03841-4 · Cited by 391

Thrombocytopenia following Pfizer and Moderna SARS‐CoV ‐2 vaccination

Lee, E., Cines, D. B., Gernsheimer, T., Kessler, C. M., Michel, M., Tarantino, M. D., Semple, J. W., Arnold, D. M., Godeau, B., Lambert, M. P., et al. (2021) · American Journal of Hematology · doi:10.1002/ajh.26132 · Cited by 387

mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar

Chemaitelly, H., Yassine, H. M., Benslimane, F. M., Al Khatib, H. A., Tang, P., Hasan, M. R., Malek, J. A., Coyle, P., Ayoub, H. H., Al Kanaani, Z., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01446-y · Cited by 386

Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial

Ella, R., Reddy, S., Blackwelder, W. C., Potdar, V. A., Yadav, P. D., Sarangi, V., Aileni, V. K., Kanungo, S., Rai, S., Reddy, P., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)02000-6 · Cited by 385

SARS-CoV-2 mRNA Vaccines Foster Potent Antigen-Specific Germinal Center Responses Associated with Neutralizing Antibody Generation

Lederer, K., Castaño, D., Gómez Atria, D., Oguin, T. H., Wang, S., Manzoni, T. B., Muramatsu, H., Hogan, M. J., Amanat, F., Cherubin, P., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.11.009 · Cited by 383

Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals

Kustin, T., Harel, N., Finkel, U., Perchik, S., Harari, S., Tahor, M., Caspi, I., Levy, R., Leshchinsky, M., Ken Dror, S., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01413-7 · Cited by 373

Effectiveness of COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe outcomes with variants of concern in Ontario

Nasreen, S., Chung, H., He, S., Brown, K. A., Gubbay, J. B., Buchan, S. A., Fell, D. B., Austin, P. C., Schwartz, K. L., Sundaram, M. E., et al. (2022) · Nature Microbiology · doi:10.1038/s41564-021-01053-0 · Cited by 360

Effects of common mutations in the SARS-CoV-2 Spike RBD and its ligand, the human ACE2 receptor on binding affinity and kinetics

Barton, M. I., MacGowan, S. A., Kutuzov, M. A., Dushek, O., Barton, G. J., & van der Merwe, P. A. (2021) · eLife · doi:10.7554/elife.70658 · Cited by 346

BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully vaccinated hospitalized COVID-19 patients in Israel

Brosh‐Nissimov, T., Orenbuch‐Harroch, E., Chowers, M., Elbaz, M., Nesher, L., Stein, M., Maor‬‏, ‪., Cohen, R., Hussein, K., Weinberger, M., et al. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.06.036 · Cited by 326

D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization

Weissman, D., Alameh, M.-G., de Silva, T., Collini, P., Hornsby, H., Brown, R., LaBranche, C. C., Edwards, R. J., Sutherland, L., Santra, S., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2020.11.012 · Cited by 324

D614G Mutation Alters SARS-CoV-2 Spike Conformation and Enhances Protease Cleavage at the S1/S2 Junction

Gobeil, S., Janowska, K., McDowell, S., Mansouri, K., Parks, R., Manne, K., Stalls, V., Kopp, M., Henderson, R. C., Edwards, R. J., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108630 · Cited by 324

Influence of immune aging on vaccine responses

Gustafson, C. E., Kim, C., Weyand, C. M., & Goronzy, J. J. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.03.017 · Cited by 292

Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant — National Healthcare Safety Network, March 1–August 1, 2021

Nanduri, S. A., Pilishvili, T., Derado, G., Soe, M. M., Dollard, P., Wu, H., Li, Q., Bagchi, S., Dubendris, H., Link‐Gelles, R., et al. (2021) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7034e3 · Cited by 284

Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data

Shaw, R. H., Stuart, A. S. V., Greenland, M., Liu, X., Nguyen‐Van‐Tam, J. S., & Snape, M. D. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01115-6 · Cited by 279

Acute Allergic Reactions to mRNA COVID-19 Vaccines

Blumenthal, K. G., Robinson, L. B., Camargo, C. A., Shenoy, E. S., Banerji, A., Landman, A., & Wickner, P. G. (2021) · JAMA · doi:10.1001/jama.2021.3976 · Cited by 274

Delayed Large Local Reactions to mRNA-1273 Vaccine against SARS-CoV-2

Blumenthal, K. G., Freeman, E. E., Saff, R. R., Robinson, L. B., Wolfson, A. R., Foreman, R. K., Hashimoto, D. M., Banerji, A., Li, L., Anvari, S., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2102131 · Cited by 269

Intranasal ChAdOx1 nCoV-19/AZD1222 vaccination reduces viral shedding after SARS-CoV-2 D614G challenge in preclinical models

van Doremalen, N., Purushotham, J. N., Schulz, J. E., Holbrook, M. G., Bushmaker, T., Carmody, A., Port, J. R., Yinda, C. K., Okumura, A., Saturday, G. A., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abh0755 · Cited by 264

A human coronavirus evolves antigenically to escape antibody immunity

(2021) · doi:10.1371/journal.ppat.1009453 · Cited by 258

A human coronavirus evolves antigenically to escape antibody immunity

Eguia, R., Crawford, K. H. D., Stevens-Ayers, T., Kelnhofer-Millevolte, L., Greninger, A. L., Englund, J. A., Boeckh, M. J., & Bloom, J. D. (2020) · doi:10.1101/2020.12.17.423313 · Cited by 258

Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses

Saunders, K. O., Lee, E., Parks, R., Martinez, D. R., Li, D., Chen, H., Edwards, R. J., Gobeil, S., Barr, M., Mansouri, K., et al. (2021) · Nature · doi:10.1038/s41586-021-03594-0 · Cited by 253

Analysis of SARS-CoV-2 variant mutations reveals neutralization escape mechanisms and the ability to use ACE2 receptors from additional species

Wang, R., Zhang, Q., Ge, J., Ren, W., Zhang, R., Lan, J., Ju, B., Su, B., Yu, F., Chen, P., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.06.003 · Cited by 240

Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COV2.S Vaccination

Barouch, D. H., Stephenson, K. E., Sadoff, J., Yu, J., Chang, A., Gebre, M., McMahan, K., Liu, J., Chandrashekar, A., Patel, S., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2108829 · Cited by 237

The Spike D614G mutation increases SARS-CoV-2 infection of multiple human cell types

Daniloski, Z., Jordan, T. X., Ilmain, J. K., Guo, X., Bhabha, G., tenOever, B. R., & Sanjana, N. E. (2021) · eLife · doi:10.7554/elife.65365 · Cited by 233

SARS-CoV-2 antigen exposure history shapes phenotypes and specificity of memory CD8+ T cells

Minervina, A. A., Pogorelyy, M. V., Kirk, A. M., Crawford, J. C., Allen, E. K., Chou, C., Mettelman, R. C., Allison, K., Lin, C.-Y., Brice, D. C., et al. (2022) · Nature Immunology · doi:10.1038/s41590-022-01184-4 · Cited by 221

Neutralization of the SARS-CoV-2 Mu Variant by Convalescent and Vaccine Serum

Uriu, K., Kimura, I., Shirakawa, K., Takaori-Kondo, A., Nakada, T.-A., Kaneda, A., Nakagawa, S., & Sato, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2114706 · Cited by 214

Myocarditis Temporally Associated With COVID-19 Vaccination

Rosner, C. M., Genovese, L. D., Tehrani, B. N., Atkins, M. B., Bakhshi, H., Chaudhri, S., Damluji, A. A., de Lemos, J. A., Desai, S., Emaminia, A., et al. (2021) · Circulation · doi:10.1161/circulationaha.121.055891 · Cited by 213

Covid-19: The E484K mutation and the risks it poses

Wise, J. (2021) · BMJ · doi:10.1136/bmj.n359 · Cited by 211

Functional evaluation of the P681H mutation on the proteolytic activation of the SARS-CoV-2 variant B.1.1.7 (Alpha) spike

Lubinski, B., Fernandes, M. H. V., Frazier, L. E., Tang, T., Daniel, S., Diel, D. G., Jaimes, J. A., & Whittaker, G. R. (2021) · iScience · doi:10.1016/j.isci.2021.103589 · Cited by 209

The SARS-CoV-2 Spike protein has a broad tropism for mammalian ACE2 proteins

Conceicao, C., Thakur, N., Human, S., Kelly, J. T., Logan, L., Bialy, D., Bhat, S., Stevenson-Leggett, P., Zagrajek, A. K., Hollinghurst, P., et al. (2020) · PLoS Biology · doi:10.1371/journal.pbio.3001016 · Cited by 207

Evolutionary and structural analyses of SARS-CoV-2 D614G spike protein mutation now documented worldwide

Isabel, S., Graña-Miraglia, L., Gutierrez, J. M., Bundalovic-Torma, C., Groves, H. E., Isabel, M. R., Eshaghi, A., Patel, S. N., Gubbay, J. B., Poutanen, T., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-70827-z · Cited by 204

Isolation and Characterization of 2019-nCoV-like Coronavirus from Malayan PangolinsPreprint

Xiao, K., Zhai, J., Feng, Y., Zhou, N., Zhang, X., Zou, J., Li, N., Guo, Y., Li, X., Shen, X., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.02.17.951335 · Cited by 200

New COVID-19 Cases and Hospitalizations Among Adults, by Vaccination Status — New York, May 3–July 25, 2021

Rosenberg, E. S., Holtgräve, D. R., Dorabawila, V., Conroy, M., Greene, D., Lutterloh, E. C., Backenson, B. P., Hoefer, D., Morne, J. E., Bauer, U. E., et al. (2021) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7034e1 · Cited by 198

Clinical Assessment of a Novel Recombinant Simian Adenovirus ChAdOx1 as a Vectored Vaccine Expressing Conserved Influenza A Antigens

Antrobus, R., Coughlan, L., Berthoud, T. K., Dicks, M. D. J., Hill, A. V. S., Lambe, T., & Gilbert, S. C. (2013) · Molecular Therapy · doi:10.1038/mt.2013.284 · Cited by 197

SARS-CoV-2 gene content and COVID-19 mutation impact by comparing 44 Sarbecovirus genomes

Jungreis, I., Sealfon, R. S. G., & Kellis, M. (2021) · Nature Communications · doi:10.1038/s41467-021-22905-7 · Cited by 193

Role of the platelet chemokine platelet factor 4 (PF4) in hemostasis and thrombosis

Kowalska, M. A., Rauova, L., & Poncz, M. (2009) · Thrombosis Research · doi:10.1016/j.thromres.2009.11.023 · Cited by 184

ChAdOx1 interacts with CAR and PF4 with implications for thrombosis with thrombocytopenia syndrome

Baker, A. T., Boyd, R. J., Sarkar, D., Teijeira, A., Chan, C. K., Bates, E., Waraich, K., Vant, J., Wilson, E., Truong, C. D., et al. (2021) · Science Advances · doi:10.1126/sciadv.abl8213 · Cited by 178

Exploring the Natural Origins of SARS-CoV-2 in the Light of Recombination

Lytras, S., Hughes, J., Martin, D. P., Swanepoel, P., de Klerk, A., Lourens, R., Pond, S. L. K., Xia, W., Jiang, X., & Robertson, D. L. (2022) · Genome Biology and Evolution · doi:10.1093/gbe/evac018 · Cited by 174

Thromboembolism and the Oxford–AstraZeneca COVID-19 vaccine: side-effect or coincidence?

Østergaard, S. D., Schmidt, M., Horváth–Puhó, E., Thomsen, R. W., & Sørensen, H. T. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00762-5 · Cited by 161

T-Helper Cell Subset Response Is a Determining Factor in COVID-19 Progression

Gil‐Etayo, F. J., Suàrez-Fernández, P., Cabrera-Marante, Ó., Arroyo‐Sánchez, D., Garcinuño, S., Naranjo, L., Pleguezuelo, D. E., Allende, L. M., Mancebo, E., Lalueza, A., et al. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.624483 · Cited by 157

SARS-CoV-2 one year on: evidence for ongoing viral adaptation

Peacock, T. P., Penrice-Randal, R., Hiscox, J. A., & Barclay, W. (2021) · Journal of General Virology · doi:10.1099/jgv.0.001584 · Cited by 155

Evaluation of COVID-19 vaccination strategies with a delayed second dose

Moghadas, S. M., VILCHES, T. N., Zhang, K., Nourbakhsh, S., Sah, P., Fitzpatrick, M. C., & Galvani, A. P. (2021) · PLoS Biology · doi:10.1371/journal.pbio.3001211 · Cited by 154

Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates

He, Q., Mao, Q., An, C., Zhang, J., Gao, F., Bian, L., Li, C., Liang, Z., Xu, M., & Wang, J. (2021) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.1902245 · Cited by 152

Evaluation of COVID-19 vaccination strategies with a delayed second dose

Moghadas, S., Vilches, T., Zhang, K., et al. (2021) · medRxiv · doi:10.1101/2021.01.27.21250619 · Cited by 146

Extended interval BNT162b2 vaccination enhances peak antibody generation

Parry, H., Bruton, R. K., Stephens, C., Bentley, C., Brown, K. E., Amirthalingam, G., Hallis, B., Otter, A. D., Zuo, J., & Moss, P. A. H. (2022) · npj Vaccines · doi:10.1038/s41541-022-00432-w · Cited by 146

Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera

Xie, X., Zou, J., Fontes-Garfias, C. R., Xia, H., Swanson, K. A., Cutler, M., Cooper, D., Menachery, V. D., Weaver, S., Dormitzer, P. R., et al. (2021) · doi:10.1101/2021.01.07.425740 · Cited by 143

Effect of Antigenic Drift on Influenza Vaccine Effectiveness in the United States—2019–2020

Tenforde, M. W., Kondor, R. J. G., Chung, J. R., Zimmerman, R. K., Nowalk, M. P., Jackson, M. L., Jackson, L. A., Monto, A. S., Martin, E. T., Belongia, E. A., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1884 · Cited by 141

An interactive website tracking COVID-19 vaccine development

Shrotri, M., Swinnen, T., Kampmann, B., & Parker, E. P. K. (2021) · The Lancet Global Health · doi:10.1016/s2214-109x(21)00043-7 · Cited by 139

SARS-CoV-2 501Y.V2 (B.1.351) elicits cross-reactive neutralizing antibodiesPreprint

Moyo-Gwete, T., Madzivhandila, M., Makhado, Z., Ayres, F., Mhlanga, D., Oosthuysen, B., Lambson, B., Kgagudi, P., Tegally, H., Iranzadeh, A., et al. (2021) · bioRxiv · doi:10.1101/2021.03.06.434193 · Cited by 134

Neutralization of SARS-CoV-2 Variants by mRNA and Adenoviral Vector Vaccine-Elicited Antibodies

Tada, T., Zhou, H., Samanovic, M. I., Dcosta, B. M., Cornelius, A. R., Herati, R. S., Mulligan, M. J., & Landau, N. R. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.797589 · Cited by 133

SARS-CoV-2 immune evasion by variant B.1.427/B.1.429Preprint

McCallum, M., Bassi, J., Marco, A. D., Chen, A., Walls, A. C., di Iulio, J., Tortorici, M. A., Navarro, M.-J., Silacci-Fregni, C., Saliba, C., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.31.437925 · Cited by 128

Cross-Reactive Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351)

Moyo-Gwete, T., Madzivhandila, M., Makhado, Z., Ayres, F., Mhlanga, D., Oosthuysen, B., Lambson, B. E., Kgagudi, P., Tegally, H., Iranzadeh, A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2104192 · Cited by 128

Antibody Responses to SARS-CoV-2 mRNA Vaccines Are Detectable in Saliva

Ketas, T. J., Chaturbhuj, D. N., Portillo, V. M. C., Francomano, E., Golden, E. B., Chandrasekhar, S., Debnath, G., Diaz-Tapia, R., Yasmeen, A., Kramer, K. D., et al. (2021) · Pathogens and Immunity · doi:10.20411/pai.v6i1.441 · Cited by 126

Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination

Gorman, M. J., Patel, N., Guebre‐Xabier, M., Zhu, A. L., Atyeo, C. G., Pullen, K. M., Loos, C., Goez-Gazi, Y., Carrion, R., Tian, J.-H., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100405 · Cited by 121

A Novel Bat Coronavirus Closely Related to SARS-CoV-2 Contains Natural Insertions at the S1/S2 Cleavage Site of the Spike Protein

Zhou, H., Chen, X., Hu, T., Li, J., Song, H., Liu, Y., Wang, P., Liu, D., Yang, J. H., Holmes, E. C., et al. (2020) · Current Biology · doi:10.1016/j.cub.2020.09.030 · Cited by 118

From COVID-19 to Cancer mRNA Vaccines: Moving From Bench to Clinic in the Vaccine Landscape

Chakraborty, C., Sharma, A. R., Bhattacharya, M., & Lee, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.679344 · Cited by 114

Neutralizing Activity of Sera from Sputnik V-Vaccinated People against Variants of Concern (VOC: B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.617.3) and Moscow Endemic SARS-CoV-2 Variants

Gushchin, V. А., Dolzhikova, I. V., Shchetinin, A. M., Odintsova, A. S., Siniavin, A. E., Nikiforova, M. A., Pochtovyi, A. A., Shidlovskaya, E. V., Kuznetsova, N. A., Burgasova, O., et al. (2021) · Vaccines · doi:10.3390/vaccines9070779 · Cited by 110

Effectiveness of COVID-19 vaccines against variants of concern, CanadaPreprint

Nasreen, S., Chung, H., He, S., et al. (2021) · medRxiv · doi:10.1101/2021.06.28.21259420 · Cited by 108

Extended interval BNT162b2 vaccination enhances peak antibody generation in older peoplePreprint

Parry, H., Bruton, R., Stephens, C., et al. (2021) · medRxiv · doi:10.1101/2021.05.15.21257017 · Cited by 106

SARS-CoV-2 spike P681R mutation, a hallmark of the Delta variant, enhances viral fusogenicity and pathogenicityPreprint

Saito, A., Irie, T., Suzuki, R., Maemura, T., Nasser, H., Uriu, K., Kosugi, Y., Shirakawa, K., Sadamasu, K., Kimura, I., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.06.17.448820 · Cited by 106

Immunogenicity and protective efficacy of inactivated SARS-CoV-2 vaccine candidate, BBV152 in rhesus macaques

Yadav, P. D., Ella, R., Kumar, S., Patil, D., Mohandas, S., Shete, A. M., Vadrevu, K. M., Bhati, G., Sapkal, G. N., Kaushal, H., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21639-w · Cited by 105

Emergence of the E484K mutation in SARS-COV-2-infected immunocompromised patients treated with bamlanivimab in Germany

Jensen, B. O., Lübke, N., Feldt, T., Keitel, V., Brandenburger, T., Kindgen‐Milles, D., Lutterbeck, M., Freise, N. F., Schoeler, D., Haas, R. R., et al. (2021) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2021.100164 · Cited by 102

Comparison of Neutralizing Antibody Titers Elicited by mRNA and Adenoviral Vector Vaccine against SARS-CoV-2 Variants

Tada, T., Zhou, H., Samanovic, M., et al. (2021) · bioRxiv · doi:10.1101/2021.07.19.452771 · Cited by 97

New COVID-19 Cases and Hospitalizations Among Adults, by Vaccination Status — New York, May 3–July 25, 2021

Rosenberg, E. S., Holtgräve, D. R., Dorabawila, V., Conroy, M., Greene, D., Lutterloh, E. C., Backenson, B. P., Hoefer, D., Morne, J. E., Bauer, U. E., et al. (2021) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7037a7 · Cited by 95

SARS-CoV-2 B.1.617.2 Delta variant replication, sensitivity to neutralising antibodies and vaccine breakthrough

Mlcochova, P., Kemp, S., Dhar, M. S., Papa, G., Meng, B., Mishra, S., Whittaker, C., Mellan, T., Ferreira, I., Datir, R., et al. (2021) · doi:10.1101/2021.05.08.443253 · Cited by 90

Introduction of Two Prolines and Removal of the Polybasic Cleavage Site Lead to Higher Efficacy of a Recombinant Spike-Based SARS-CoV-2 Vaccine in the Mouse Model

Amanat, F., Strohmeier, S., Rathnasinghe, R., Schotsaert, M., Coughlan, L., García‐Sastre, A., & Krammer, F. (2021) · mBio · doi:10.1128/mbio.02648-20 · Cited by 86

Fine-tuning the spike: role of the nature and topology of the glycan shield in the structure and dynamics of the SARS-CoV-2 S

Harbison, A. M., Fogarty, C. A., Phung, T. K., Satheesan, A., Schulz, B. L., & Fadda, E. (2021) · Chemical Science · doi:10.1039/d1sc04832e · Cited by 86

Humoral Immunogenicity and Efficacy of a Single Dose of ChAdOx1 MERS Vaccine Candidate in Dromedary Camels

Alharbi, N. K., Qasim, I., Almasoud, A. S., Aljami, H. A., Alenazi, M. W., Alhafufi, A. N., Aldibasi, O. S., Hashem, A. M., Kasem, S., Albrahim, R., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-52730-4 · Cited by 81

Impact of original, B.1.1.7, and B.1.351/P.1 SARS-CoV-2 lineages on vaccine effectiveness of two doses of COVID-19 mRNA vaccines: Results from a nationwide case-control study in France

Charmet, T., Schaeffer, L., Grant, R., Galmiche, S., Chény, O., Von Platen, C., Maurizot, A., Rogoff, A., Omar, F., David, C., et al. (2021) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2021.100171 · Cited by 80

Vaccine effectiveness after 1 st and 2 nd dose of the BNT162b2 mRNA Covid-19 Vaccine in long-term care facility residents and healthcare workers – a Danish cohort study

Moustsen-Helms, I. R., Emborg, H.-D., Nielsen, J., Nielsen, K. F., Krause, T. G., Mølbak, K., Møller, K. L., Berthelsen, A.-S. N., & Valentiner-Branth, P. (2021) · doi:10.1101/2021.03.08.21252200 · Cited by 79

Quantifying the transmission advantage associated with N501Y substitution of SARS-CoV-2 in the UK: an early data-driven analysis

Zhao, S., Lou, J., Cao, L., Zheng, H., Chong, K. C., Chen, Z., Chan, R. W. Y., Zee, B. C.-Y., Chan, P. K. S., & Wang, M. H. (2021) · Journal of Travel Medicine · doi:10.1093/jtm/taab011 · Cited by 77

Emergence and phenotypic characterization of the global SARS-CoV-2 C.1.2 lineage

Scheepers, C., Everatt, J., Amoako, D. G., Tegally, H., Wibmer, C. K., Mnguni, A., Ismail, A., Mahlangu, B., Lambson, B. E., Richardson, S. I., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29579-9 · Cited by 76

Are vaccines safe in patients with Long COVID? A prospective observational studyPreprint

Arnold, D., Milne, A., Samms, E., Stadon, L. J., Maskell, N. A., & Hamilton, F. (2021) · medRxiv · doi:10.1101/2021.03.11.21253225 · Cited by 75

An emerging SARS-CoV-2 mutant evading cellular immunity and increasing viral infectivityPreprint

Motozono, C., Toyoda, M., Zahradník, J., Ikeda, T., Saito, A., Tan, T. S., Ngare, I., Nasser, H., Kimura, I., Uriu, K., et al. (2021) · bioRxiv · doi:10.1101/2021.04.02.438288 · Cited by 74

AstraZeneca vaccine: Blood clots are “extremely rare” and benefits outweigh risks, regulators conclude

Mahase, E. (2021) · BMJ · doi:10.1136/bmj.n931 · Cited by 73

Public health impact of delaying second dose of BNT162b2 or mRNA-1273 covid-19 vaccine: simulation agent based modeling study

Brufau, S. R., Chopra, A., Ryu, A. J., Gel, E. S., Raskar, R., Kremers, W. K., Anderson, K. S., Subramanian, J., Krishnamurthy, B., Singh, A., et al. (2021) · BMJ · doi:10.1136/bmj.n1087 · Cited by 71

Functional evaluation of the P681H mutation on the proteolytic activation the SARS-CoV-2 variant B.1.1.7 (Alpha) spikePreprint

Lubinski, B., Fernandes, M. H. V., Frazier, L. E., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.04.06.438731 · Cited by 71

Increased transmission of SARS-CoV-2 lineage B.1.1.7 (VOC 2020212/01) is not accounted for by a replicative advantage in primary airway cells or antibody escapePreprint

Brown, J. C., Goldhill, D. H., Zhou, J., Peacock, T. P., Frise, R., Goonawardane, N., Baillon, L., Kugathasan, R., Pinto, A., McKay, P. F., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.02.24.432576 · Cited by 70

COVID ‐19: vaccination problems

Brüssow, H. (2021) · Environmental Microbiology · doi:10.1111/1462-2920.15549 · Cited by 69

Delayed Second Dose versus Standard Regimen for Covid-19 Vaccination

Kadire, S. R., Wachter, R. M., & Lurie, N. (2021) · New England Journal of Medicine · doi:10.1056/nejmclde2101987 · Cited by 68

Use of adenovirus type-5 vectored vaccines: a cautionary tale

Buchbinder, S., McElrath, M. J., Dieffenbach, C. W., & Corey, L. (2020) · The Lancet · doi:10.1016/s0140-6736(20)32156-5 · Cited by 62

Impact of South African 501.V2 Variant on SARS-CoV-2 Spike Infectivity and Neutralization: A Structure-based Computational AssessmentPreprint

Cheng, M. H., Krieger, J., Kaynak, B., Arditi, M., & Bahar, İ. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.01.10.426143 · Cited by 57

Pros and Cons of Adenovirus-Based SARS-CoV-2 Vaccines

Kremer, E. J. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.10.002 · Cited by 53

Reduced antibody cross-reactivity following infection with B.1.1.7 than with parental SARS-CoV-2 strains

Faulkner, N., Ng, K. W., Wu, M. Y., Harvey, R., Margaritis, M., Paraskevopoulou, S., Houlihan, C., Hussain, S., Greco, M., Bolland, W., et al. (2021) · eLife · doi:10.7554/elife.69317 · Cited by 52

The SARS-CoV-2 Spike protein has a broad tropism for mammalian ACE2 proteinsPreprint

Conceicao, C., Thakur, N., Human, S., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.06.17.156471 · Cited by 51

Intranasal ChAdOx1 nCoV-19/AZD1222 vaccination reduces shedding of SARS-CoV-2 D614G in rhesus macaquesPreprint

van Doremalen, N., Purushotham, J. N., Schulz, J. E., Holbrook, M. G., Bushmaker, T., Carmody, A., Port, J. R., Yinda, C. K., Okumura, A., Saturday, G. A., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.01.09.426058 · Cited by 50

Exploring the natural origins of SARS-CoV-2 in the light of recombinationPreprint

Lytras, S., Hughes, J., Martin, D. P., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.01.22.427830 · Cited by 50

Efficacy, safety, and lot to lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): a double-blind, randomised, controlled phase 3 trialPreprint

Ella, R., Reddy, S., Blackwelder, W., Potdar, V., Yadav, P. D., Sarangi, V., Aileni, V. K., Kanungo, S., Rai, S., Reddy, P., et al. (2021) · medRxiv · doi:10.1101/2021.06.30.21259439 · Cited by 50

High level of protection against COVID-19 after two doses of BNT162b2 vaccine in the working age population – first results from a cohort study in Southern Sweden

Björk, J., Inghammar, M., Moghaddassi, M., Rasmussen, M., Malmqvist, U. P., & Kahn, F. (2021) · Scandinavian Journal of Infectious Diseases · doi:10.1080/23744235.2021.1982144 · Cited by 48

Possible host-adaptation of SARS-CoV-2 due to improved ACE2 receptor binding in mink

Welkers, M. R. A., Han, A. X., Reusken, C. B. E. M., & Eggink, D. (2020) · Virus Evolution · doi:10.1093/ve/veaa094 · Cited by 47

The continuous evolution of SARS-CoV-2 in South Africa: a new lineage with rapid accumulation of mutations of concern and global detectionPreprint

Scheepers, C., Everatt, J., Amoako, D., et al. (2021) · medRxiv · doi:10.1101/2021.08.20.21262342 · Cited by 43

Detection of persistent SARS-CoV-2 IgG antibodies in oral mucosal fluid and upper respiratory tract specimens following COVID-19 mRNA vaccination

Mades, A., Chellamathu, P., Kojima, N., Lopez, L., MacMullan, M. A., Denny, N., Angel, A. N., Santacruz, M., Casian, J. G., Brobeck, M., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-03931-3 · Cited by 42

Simultaneous evaluation of antibodies that inhibit SARS-CoV-2 variants via multiplex assay

López, E., Haycroft, E. R., Adair, A., Mordant, F. L., O’Neill, M. T., Pymm, P., Redmond, S. J., Lee, W. S., Gherardin, N. A., Wheatley, A. K., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.150012 · Cited by 38

Advances in COVID-19 mRNA vaccine development

Fang, E., Liu, X., Li, M., Zhang, Z., Song, L., Zhu, B., Wu, X., Liu, J., Zhao, D., & Li, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00950-y · Cited by 601

Lipid nanoparticles: Composition, formulation, and application

Xu, S., Hu, Z., Song, F., Xu, Y. G., & Han, X. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101463 · Cited by 115

SARS-CoV-2 Vaccines, Vaccine Development Technologies, and Significant Efforts in Vaccine Development during the Pandemic: The Lessons Learned Might Help to Fight against the Next Pandemic

Chakraborty, C., Bhattacharya, M., & Dhama, K. (2023) · Vaccines · doi:10.3390/vaccines11030682 · Cited by 112

Omicron (B.1.1.529) variant of SARS‐CoV‐2: Concerns, challenges, and recent updates

Mohapatra, R. K., Tiwari, R., Sarangi, A. K., Islam, M. R., Chakraborty, C., & Dhama, K. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27633 · Cited by 83

Development and applications of mRNA treatment based on lipid nanoparticles

Wang, Z., Ma, W., Fu, X., Qi, Y., Zhao, Y., & Zhang, S. (2023) · Biotechnology Advances · doi:10.1016/j.biotechadv.2023.108130 · Cited by 57

nSARS-CoV-2 and COVID-19 Pandemic: From Emergence to Vaccination

Shahid, I. (2022) · Dr Sulaiman Al Habib Medical Journal · doi:10.1007/s44229-022-00006-x

The variants of SARS‐CoV‐2 and the challenges of vaccines

Han, X., & Ye, Q. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27513 · Cited by 37

An Overview of Vaccines against SARS-CoV-2 in the COVID-19 Pandemic Era

Pascual‐Iglesias, A., Cantón, J., Ortega‐Prieto, A. M., Jiménez-Guardeño, J. M., & Regla-Nava, J. Á. (2021) · Pathogens · doi:10.3390/pathogens10081030 · Cited by 50

Fast-track development of vaccines for SARS-CoV-2: The shots that saved the world

Chavda, V. P., Yao, Q., Vora, L. K., Apostolopoulos, V., Patel, C. A., Bezbaruah, R., Patel, A., & Chen, Z. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.961198 · Cited by 63

SARS-CoV-2 Vaccines, Vaccine Development Technologies, and Significant Efforts in Vaccine Development during the Pandemic: The Lessons Learned Might Help to Fight against the Next Pandemic

Chakraborty, C., Bhattacharya, M., & Dhama, K. (2023) · Vaccines · doi:10.3390/vaccines11030682 · Cited by 112